<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since <z:hpo ids='HP_0000822'>hypertension</z:hpo> and/or <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> are risk factors for <z:hpo ids='HP_0001297'>stroke</z:hpo>, we examined whether the putative neuroprotectant, <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> (NAm), could protect spontaneously hypertensive rats (SHR) or diabetic Fischer 344 rats against focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> using a model of permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) </plain></SENT>
<SENT sid="1" pm="."><plain>Intravenous NAm given 2 h after MCAo significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume of SHR (750 mg/kg, 31%, P&lt;0.01) and diabetic (500 mg/kg, 56%, P&lt;0.01) as well as non-diabetic (500 mg/kg, 73%, P&lt;0.01) Fischer 344 rats when compared with saline-injected controls </plain></SENT>
<SENT sid="2" pm="."><plain>Thus delayed treatment with NAm protected hypertensive and hyperglycemic rats against a robust model of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>